These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33946532)

  • 21. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
    Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
    Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
    Peng H; He X; Wang Q
    Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of autophagy in cervical, endometrial and ovarian cancer.
    Orfanelli T; Jeong JM; Doulaveris G; Holcomb K; Witkin SS
    Int J Cancer; 2014 Aug; 135(3):519-28. PubMed ID: 24122662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences the TNFα-RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells.
    Smith AD; Lu C; Payne D; Paschall AV; Klement JD; Redd PS; Ibrahim ML; Yang D; Han Q; Liu Z; Shi H; Hartney TJ; Nayak-Kapoor A; Liu K
    Cancer Res; 2020 Aug; 80(15):3145-3156. PubMed ID: 32554751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.
    Markman M
    Womens Health (Lond); 2016 Jul; 12(4):396-9. PubMed ID: 27638892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
    Li F; Zhao Y; Wei L; Li S; Liu J
    Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.
    Duenas-Gonzalez A; Medina-Franco JL; Chavez-Blanco A; Dominguez-Gomez G; Fernández-de Gortari E
    Expert Opin Pharmacother; 2016; 17(3):323-38. PubMed ID: 26559668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
    Qu P; Wang LZ; Lin PC
    Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and age-related chronic inflammatory disorders.
    Salminen A; Kaarniranta K; Kauppinen A
    Int Immunopharmacol; 2018 Aug; 61():231-240. PubMed ID: 29894862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy.
    Wu K; Tan MY; Jiang JT; Mu XY; Wang JR; Zhou WJ; Wang X; Li MQ; He YY; Liu ZH
    Clin Immunol; 2018 Aug; 193():60-69. PubMed ID: 29410331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin.
    Zhou J; Donatelli SS; Gilvary DL; Tejera MM; Eksioglu EA; Chen X; Coppola D; Wei S; Djeu JY
    Sci Rep; 2016 Jul; 6():29521. PubMed ID: 27405665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
    Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
    Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells.
    Lee A; Park H; Lim S; Lim J; Koh J; Jeon YK; Yang Y; Lee MS; Lim JS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers.
    Yamaguchi K; Matsumoto Y; Suzuki R; Nishida H; Omata D; Inaba H; Kukita A; Tanikawa M; Sone K; Oda K; Osuga Y; Maruyama K; Fujii T
    Cancer Sci; 2021 Jun; 112(6):2493-2503. PubMed ID: 33793049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells.
    Mise Y; Hamanishi J; Daikoku T; Takamatsu S; Miyamoto T; Taki M; Yamanoi K; Yamaguchi K; Ukita M; Horikawa N; Abiko K; Murakami R; Furutake Y; Hosoe Y; Terakawa J; Kagabu M; Sugai T; Osakabe M; Fujiwara H; Matsumura N; Mandai M; Baba T
    Carcinogenesis; 2022 Aug; 43(7):647-658. PubMed ID: 35353883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
    Wang L; Hu D; Xie B; Xie L
    Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bovine lactoferrin and lactoferrin peptides affect endometrial and cervical cancer cell lines.
    Ramírez-Sánchez DA; Arredondo-Beltrán IG; Canizalez-Roman A; Flores-Villaseñor H; Nazmi K; Bolscher JGM; León-Sicairos N
    Biochem Cell Biol; 2021 Feb; 99(1):149-158. PubMed ID: 33307991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.